Markets
Citi equity analysts on the key valuation issue facing the market.
Analysis! (CSA Archive/Getty Images)

Citi’s US market analyst on the key valuation test facing the market

“It kind of comes down to, what inning do you think we are in this AI game?”

Citi US equity strategist Scott Chronert feels your pain.

The market is obviously expensive. But it’s been that way for some time.

And anyone who sold out of discomfort with P/E ratios in the 20s — which the S&P 500 has sported since January 2024 — has missed out on a gain of more than 35%.

In a recent note, Chronert spotlighted the aggressive growth expectations — what he calls an “earnings obligation” — that seem to have supported stocks in recent months, but will have to be justified by Q3 earnings results when they start rolling in just under three weeks.

We got him on the phone to talk a bit about risk that expectations may have gotten too optimistic, setting stocks up for an ugly collision with reality.

Here are highlights from our conversation, edited for clarity and concision:

Sherwood News: What’s the key question for the market right now, as you see it?

Scott Chronert: It kind of comes down to, what inning do you think we are in this AI game, AI infrastructure build-out. And the Citi house view is that we’re still early innings.

So when I look at that setup, therefore, I have to consider whether these companies will keep surprising to the upside on earnings the way they have. That’s sort of a shorter-term dynamic.

I also have to weigh in the persistency of that growth. Can these companies continue to demonstrate this kind of growth over the next several years?

Historically, when you look at periods like this where there have been seemingly excessive valuations — think about the tech bubble or the 2021 rally coming out of Covid — what ends up happening is that the fundamentals don’t persist.

Sherwood: So when you say the fundamentals “don’t persist,” essentially you’re saying strong sales and profits don’t continue to be strong. They fall off.

Chronert: Yeah, they fall apart. And historically speaking, that’s where you get your bigger downdrafts, because you’ve been embedding an expectation in the market that doesn’t get fulfilled.

Fast-forward to where we are currently and most people would say, well, gosh, this is a high-valuation market.

Sherwood: Yeah, I saw we cracked a multiple of 23x on the S&P 500 forward P/E. We haven’t really seen levels that high since the tech bubble — outside of the post-Covid boom. Where do you see similarities between the current market and the tech stock boom that got going in the late 1990s?

Chronert: Essentially in the tech bubble, we were building out internet infrastructure. This time, we’re building out AI infrastructure.

The other similarity is that it was sort of a new technology paradigm that fostered both a lot of innovation and a lot of hype, let’s say. And we’re seeing something comparable.

The difference, though, is the nature of the companies involved in the spending on the infrastructure build-out. Today you’ve got giant companies with large cash flows that are supporting a lot of the spending.

Less of the money for investment is coming from IPOs and debt issuance. More of it’s coming from existing cash or free cash flow. So it’s a healthier starting point, which I think gives the cycle more of a chance of persisting.

And if we’re looking at a protracted investment cycle that goes for another couple years, or several years, then I think it kind of sets us up for what we’re arguing is still a structural bull case for US equities.

Sherwood: Growth expectations for sales are one thing, but also it’s worth thinking about the fact that profits are at a very high level, too. Is that a potential worry?

For instance, if you look at profit margins, or absolute profit levels or profits as a share of GDP, doesn’t that raise the difficulty of keeping this profit growth going? We’re not starting from the low level where we were during Covid.

Chronert: It’s a good point, a good question.

A lot of this is going to be persistence for revenue growth combined with fairly high gross margin structures, which mean a lot of operating leverage. So what then happens is your return metrics — whether it’s return on equity, return on invested capital, pick your return metric — they begin to really, really surge. And so far, with the big capex investors, what we’re seeing is that you haven’t seen much deterioration in a lot of the profit metrics.

But there’s no question that you don’t want a very profitable business model to unwind. So that’s among the things that we’re going to have to keep an eye on.

Sherwood: In your recent note, you do say you have a nagging concern about whether the “raise” component — companies updating and lifting sales and profit forecasts as part of the quarterly reports — will satisfy the market during Q3 earnings season. Can you flesh that out for me a bit?

Chronert: The question is simply whether, as we go into the Q3 reporting period, are we going to get healthy growth projections? And will they match, or exceed, what the stocks are discounting or expecting?

Sherwood: And the only way to assess that is how the stock reacts after the numbers, right?

Chronert: Pretty much. We’re allowing for some volatility around that reporting period. But at the same time, we’ve got the Fed with its next wave of rate cuts coming, and that still sets us up for a stronger finish to the year.

Sherwood: But is there a point where we should worry that these high valuations mean we’re overpaying for future growth?

Chronert: I think the point we’re making and the way I kind of wrote that note is that if you sold just on valuation, you’ve been selling for the past year. How’s that done for you?

Sherwood: I guess it depends how the next year goes. If we crash 50% in 2026, selling the market this year will look like a pretty smart move in retrospect.

Chronert: Well, we’re saying we think this particular AI-related effect has room to run. And I think, implicitly, we’re saying it’s going to be tough to call the top.

Sherwood: Broadly, how reliant is this market on the AI story? If there were to be a setback in AI, how tough would that be for the broader market to weather?

Chronert: We’ve done some other work on that, and we’ve said almost 50% of the S&P market capitalization appears to be AI-influenced.

So essentially you’re running dual markets. You’re running a market that’s sort of all about AI as a driver, and then you’ve got the other half that has more traditional drivers. I’m probably more concerned about the AI side of the market than the non-AI side of market because of the embedded expectations we’ve been talking about.

Sherwood: Thanks very much for your time.

Chronert: Take care.

More Markets

See all Markets
markets

Nike’s China business declines for seventh straight quarter

Sportswear kingpin Nike reported results for its third quarter, which ended in February, after the bell Tuesday. The stock fell about 3% in after-hours trading.

For fiscal Q3, Nike reported:

  • Earnings of $0.35 per share, comfortably above the Wall Street consensus of $0.29 per share compiled by FactSet.

  • $11.28 billion in total revenue, roughly in line with the $11.26 billion estimate.

Nike’s sales in China — where the company earns about 15% of its revenue — fell 7% to $1.62 billion. That’s its seventh straight quarter of sales declines in the market, though this quarter’s was less than feared. The company had issued weak guidance for this quarter considering continued softness in the region.

“This quarter we took meaningful actions to improve the health and quality of our business,” said Nike CEO Elliott Hill. “The pace of progress is different across the portfolio and the areas we prioritized first continue to drive momentum.”

Nike shares are trading near decade lows this month, as tariffs continue to weigh on profits and shipping costs rise amid the war with Iran. As of Tuesday’s close, the stock was down 17% year to date.

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

Travel stocks are surging on Tuesday as oil prices fall following reports from Iranian state media that President Masoud Pezeshkian said the country has the necessary will to end this war, but would only do so with guarantees that prevent the recurrence of aggression.

The war has sent oil prices and refining margins surging this month, causing airlines and cruise lines to cut profit forecasts despite reported high demand.

Following Tuesday’s update, shares of the big four US airlines (Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines) all climbed, along with smaller rivals including JetBlue. US airlines have stopped fuel hedging in recent years, increasing their exposure to upward swings in oil prices.

Cruise stocks also rallied, with Carnival and Norwegian up more than 6% and Royal Caribbean up about 5%.

markets

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times reported Tuesday.

The potential move was previously reported by The Wall Street Journal, and teased by Health Secretary Robert F. Kennedy Jr. on the “Joe Rogan Experience” podcast in late February.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

markets

Memory stocks bounce as Bernstein analyst calls TurboQuant fears “overdone”

Memory stocks rose Tuesday, after Bernstein analysts called the recent panic over Google’s TurboQuant AI algorithm “overdone.”

Bernstein analyst Mark Newman wrote:

“[Hard disk drive] and Memory stocks have sold off significantly due in part to fears from Google’s TurboQuant report. This however, should have zero impact on HDD demand and negligible impact on NAND demand. Given the stock sell-off we see this as an attractive entry point for Seagate Technology Holdings, Western Digital and Sandisk’s and upgrade WDC to Outperform.”

All three stocks were up early Tuesday, as was memory chip maker Micron.

Todays rally stands in stark contrast to the pummeling these shares have endured over the last week, after Google Research published a technical paper on March 24 detailing its TurboQuant AI algorithm, which compresses the amount of data associated with AI operations without affecting the accuracy of AI models.

That was seen as a threat to surging AI demand for memory storage, which has supercharged prices for memory chips and memory-related stocks over the last year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.